American Resources Corporation (NASDAQ:AREC), a next generation and socially responsible supplier of rare earth and critical elements, carbon and advanced carbon materials to the new infrastructure and electrification marketplace, announced that its majority-owned ReElement Technologies LLC division has procured the necessary equipment for its initial battery element isolation and purification production train for the production of battery-grade materials (lithium, cobalt and nickel) at its critical minerals purification facility in Noblesville, Indiana.

Jeff Peterson, COO of ReElement Technologies commented, "The United States battery manufacturing marketplace is looking for a commercially-viable solution for the separation and purification of battery-grade materials, and now that we have our initial production train in our facility, we can showcase our highly effective, efficient and highly-scalable technology at commercial scale for our customer base. We are confident that once we showcase our initial production, our patented technology will be the adopted and preferred processing solution for domestic battery materials as we have already proven for domestic magnet materials."

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) announced that patient enrollment is closed in the AR-301 Phase 3 clinical study. The Company is on track to complete database lock, data analyses, and expects to disclose top-line data in December 2022. The AR-301-002 Phase 3 'ASAP-1' study compares the superiority of adjunctive use of the investigational, targeted immunotherapy candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of ventilator associated pneumonia (VAP) caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). Patients enrolled will complete their treatment and 28-day follow-up per study protocol.

"Following the protracted COVID-19 pandemic that has slowed the pace of patient enrollment in clinical trials across the world, we are pleased to reach this key milestone for the study. We are working diligently to gather data from the clinical centers and report top-line results of this landmark Phase 3 study," said Aridis' Chief Medical Officer Hasan Jafri, MD.

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, presented a recap of their concussion drug development program. Odyssey acquired the intellectual property and all rights to the drug on March 1, 2021, and since the acquisition Odyssey, has made significant progress in the development program:

• Successful completion of the pre-clinical toxicology program.
• Successfully completed IND enabling safety studies for a Phase I human trial.
• Successful development of a nanoparticle drug formulation.
• Successful development of a spray-dried formulation for intranasal delivery with our partner Upperton Ltd based in the UK.
• Successful development and GMP manufacture of a novel breath-propelled intranasal delivery device with our partner, Design Catapult, Inc.
• The novel breath-propelled intranasal delivery device proved successful in the Phase I trial.

Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8), an award-winning, industry-leading drone solutions and systems developer, is announced its involvement in The International Association of Chiefs of Police (IACP) Annual Conference and Exposition from October 15-18, 2022. IACP is the largest law enforcement event of the year. More than 16,000 public safety professionals are coming to learn about innovations and equip their departments with the latest technology for ongoing success.

During the four-day event, Draganfly will be located at booth #2928, where attendees can learn about the Company's Commander 3 XL drone and Smart Vital Intelligence technology.

“Draganfly has a long history of working with law enforcement agencies and plays a critical role in the public safety sector,” said Cameron Chell, President, and CEO of Draganfly. “Drone technology can be used for a variety of use cases within public safety. This is going to be the future of law enforcement."